Scott E. James,

M.D., Ph.D.

Hematologist-Oncologist; Assistant Clinical Professor of Hematology & Hematopoietic Cell Transplantation, City of Hope® Cancer Center Duarte

Location: City of Hope Comprehensive Cancer Center - Duarte
1500 East Duarte Road
Duarte, CA 91010

Specialties: Hematologic Oncology

Education

Medical school:

Degrees

2011, Doctor of Medicine, University of Washington School of Medicine, Seattle, Washington
2009, Doctor of Philosophy, Immunology, University of Washington School of Medicine, Seattle, Washington

Residency

2014, Internal Medicine, University of Washington, Seattle, Washington

Fellowship

2017, Hematology-Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

Professional Experience

2024–present, Assistant Clinical Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, Duarte, California
2017–2024, Assistant Attending L1, Memorial Sloan Kettering Cancer Center, New York, New York

Academic Appointments

Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation

About Me

Scott James, MD, PhD, is a hematologist-oncologist at City of Hope^® Cancer Center Duarte, where he takes a patient-centered approach to providing personalized treatment plans for patients diagnosed with leukemia and works to advance research focused on next-generation cancer therapies for hematologic malignancies.

Dr. James completed his medical and scientific training, along with his internal medicine residency, at the University of Washington in Seattle. He then pursued fellowship training in hematology and oncology at Memorial Sloan Kettering Cancer Center in New York City, where he also served as an attending physician.

By the time he joined City of Hope® in 2024, Dr. James had authored 10 peer-reviewed biomedical publications. His research, supported by the National Cancer Institute, focuses on engineering T cells to more effectively treat leukemia and lymphoma while reducing the risk of graft-versus-host disease following stem cell transplantation.

In a study published in Nature Medicine, Dr. James and his collaborators demonstrated that expressing a CD19-directed CAR in donor T cells can lower the likelihood of GVHD while maintaining anti-cancer activity. He has also filed two patent applications describing novel technologies for creating T cells with multiple programmable therapeutic functions.

Patient reviews: The patient ratings and comments on this page are obtained from an external Press Ganey^® outpatient survey provided to all eligible City of Hope patients within one to two weeks of their treatment occurrence. Raw data from the answers to the survey questions about our physicians are calculated by Press Ganey into a one- to five- star rating. In the spirit of transparency, all patient comments are posted as written by the patient, whether they are positive or negative. We only exclude comments if they are deemed to be slanderous or libelous, contain profanity or vulgar language, or do not relate to the patient's experience with the doctor involved. As a result, the comments are the views and opinions of the patients surveyed and are not endorsed by, and may not necessarily reflect the opinion of, City of Hope.